News Summaries

Chinese Cancer Drug Breakthroughs Shine at ASCO—But Stocks Keep Falling

At this year’s American Society of Clinical Oncology (ASCO) meeting, Chinese biotech firms stole the spotlight. Out of 7,239 research abstracts, 488 came from Chinese institutions – a record 6.7 % share – and companies like Hengrui, Akeso, BeiGene and Bliss unveiled high‑impact studies, including a rare plenary presentation of Akeso’s PD‑1/VEGF combo drug. Yet, instead of sparking a rally, the market kept sliding. Over the five‑day “ASCO week,” shares of many innovators dropped 20‑30 % in a single session, and the downward trend continued afterward. Why the disconnect? Investors are no longer buying hype; they want hard data that proves a drug’s safety, efficacy and commercial potential. While Chinese teams are now presenting sophisticated modalities—antibody‑drug conjugates, bispecific antibodies, radiopharmaceuticals—their pipelines still lack large‑scale Phase III trials that guarantee revenue. Capital markets also factor in geopolitical risk, domestic insurance constraints and the companies’ ability to commercialize abroad. In short, the scientific achievements are real and impressive, but without clear proof of market‑ready products, the “Oscars” of oncology research aren’t enough to lift stock prices. The industry now faces the challenge of turning breakthrough data into profitable, globally accepted medicines.

Ultra‑Cold Brain‑Like Chip Could Supercharge Quantum Computers

Scientists at the University of Hong Kong have built a tiny computer chip that works almost at absolute zero—the coldest temperature possible. Instead of using the usual tricks for low‑temperature electronics, they repurposed a standard silicon‑carbide transistor so it behaves like a neuron, firing short bursts of electricity just like brain cells do. These “spikes” are ultra‑energy‑efficient, which is a huge advantage when you’re trying to control delicate quantum bits that also need to stay extremely cold. The breakthrough, described in a new Nature Communications paper, shows that neuromorphic (brain‑inspired) circuits can operate in the same frosty environment as quantum processors, opening a path to tighter integration between the two technologies. If engineers can harness these brain‑like spikes to manage quantum computers, they could dramatically cut the power needed for error correction and data handling, making large‑scale quantum machines more practical. The research points to a future where the brain’s clever, low‑power computing style helps unlock the full potential of quantum computing, all while running at temperatures just a whisker above absolute zero.